# A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol

> **NCT07487909** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sen-Jam Pharmaceutical** · enrollment: 47 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment A- Fexofenadine HCl 60mg
- **DRUG:** Treatment B- Naproxen sodium 220mg
- **DRUG:** Treatment C- SJP-001 280mg
- **DRUG:** Treatment D- Placebo-1
- **DRUG:** Treatment E- Fexofenadine HCl 120mg
- **DRUG:** Treatment F- Naproxen sodium 440mg
- **DRUG:** Treatment G- SJP-001 560mg
- **DRUG:** Treatment H- Placebo 2

## Key facts

- **NCT ID:** NCT07487909
- **Lead sponsor:** Sen-Jam Pharmaceutical
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-30
- **Primary completion:** 2025-11-21
- **Final completion:** 2025-11-21
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07487909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07487909, "A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07487909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*